With an income increase of 168.04% in the first quarter 2026, year on year to cumulative value of $25,277 million, and with 50,000 employees, Eli Lilly And's income per employee grew on trailing twelve month basis to $ 505,534, this marks a new company high for all of 50,000 employees.
The Healthcare sector has seen employees of 28 other companies achieving higher income per employee. While Eli Lilly And's total ranking has deteriorated compared to the previous quarter from 248 to 323.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

LLY Net Income per Employee	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Net Income Change	168.04 %	50.52 %	475.34 %	90.78 %	23.02 %
Net Income per Employee (TTM) $	505,534	412,800	368,242	275,998	222,128
LLY's Total Ranking	# 323	# 248	# 334	# 338	# 393
Seq. Net Income Change	11.42 %	18.9 %	-1.38 %	105.14 %	-37.43 %

LLY Company Profile >> Back to LLY Efficiency Comparisons >> Compare LLY Net Income per Employee to its Competitors

LLY Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 29
Healthcare Sector	# 47
Overall Market	# 323

Net Income per Employee Statistics
High	Average	Low
$ 505,534	$ 94,712	$ -41,438
(Mar 31 2026)		(Dec. 31, 2008)

Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector	Income per Employee	Income 12 month ending Mar 31 2026	Number of Employees Mar 31 2026
Halozyme Therapeutics Inc	824,687.94	$ 348.843 Million	423
Prestige Consumer Healthcare Inc	785,608.77	$ 447.797 Million	570
Agenus Inc	771,518.52	$ 62.493 Million	81
Krystal Biotech Inc	762,813.56	$ 225.030 Million	295
Elite Pharmaceuticals Inc	690,349.02	$ 44.873 Million	65
Illumina Inc	666,406.25	$ 853.000 Million	1,280
Engene Therapeutics Inc	623,048.78	$ 51.090 Million	82
Spero Therapeutics Inc	609,400.00	$ 15.235 Million	25
Amgen Inc	600,000.00	$ 7,800.000 Million	13,000
Vaxart Inc	570,723.08	$ 37.097 Million	65
Entera Bio Ltd	562,590.91	$ 12.377 Million	22
Gilead Sciences Inc	542,117.65	$ 9,216.000 Million	17,000
Soleno Therapeutics Inc	527,692.31	$ 96.040 Million	182
Sanuwave Health Inc	508,163.64	$ 27.949 Million	55
Eli Lilly And Company	505,534.00	$ 25,276.700 Million	50,000
Incyte Corporation	503,437.76	$ 1,431.777 Million	2,844
Harmony Biosciences Holdings inc	496,979.52	$ 145.615 Million	293
Omeros Corporation	492,400.00	$ 86.170 Million	175
Acadia Pharmaceuticals Inc	470,739.35	$ 375.650 Million	798
Siga Technologies Inc	412,920.69	$ 20.233 Million	49
Black Hawk Acquisition Corporation	405,491.50	$ 0.811 Million	2
Neurocrine Biosciences Inc	334,300.00	$ 668.600 Million	2,000
Abeona Therapeutics Inc	292,641.59	$ 66.137 Million	226
Regeneron Pharmaceuticals Inc	287,047.37	$ 4,423.400 Million	15,410
Adma Biologics Inc	255,570.32	$ 165.354 Million	647

Date modified: 2026-08-30T14:53:01+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.